A mom donated her uterus to help another woman carry a baby—now they've met the child they made possible
Sara had donated her uterus so that Emma, who was born without one, could experience pregnancy. And now, for the first time, they were meeting face to face—with Olivia nestled between them.
Their story opens a window into a rarely seen side of motherhood. It's about bold medical innovation, the quiet strength of women who've been told 'no,' and the life-changing impact of one woman lifting another up in the most intimate way imaginable.
Emma Dolzal spent most of her life believing she would never carry a child. Born without a uterus due to a rare condition called MRKH syndrome, she had long grieved a version of motherhood that felt forever out of reach. Then she heard about a clinical trial at Penn Medicine offering uterine transplants—something that once seemed like science fiction. She applied. She hoped. And eventually, she became pregnant.
But behind that miracle was another mother: Sara Leister, a 40-year-old nurse and mom of two, who had seen a news segment about uterine transplants and felt an immediate pull. Her own family was complete, but the thought that her uterus could help another woman experience pregnancy stayed with her. So she stepped forward, volunteered, and gave away the organ that had once carried her children.
Their lives—once completely separate—were now intertwined in the most intimate way possible. Emma was able to carry and deliver a baby girl, Olivia, thanks to Sara's gift. And when the two women finally met for the first time, holding the baby they had both made possible, the gratitude between them was unmistakable.
Related: First baby born after successful uterus transplant in America
When Emma and Sara finally met in person, it wasn't in a hospital or a clinical setting. It was a room filled with emotion, with baby Olivia, wide-eyed and unaware of the miracle she represents, nestled between them.
They smiled through tears, hugged like old friends, and marveled at the child who connected their lives in such an unexpected, profound way. Olivia arrived thanks to medicine, yes—but also because of trust, timing, and a generosity beyond what most of us ever experience.
There was no need for big speeches. Just gratitude. Emma looked at Sara and saw the person who made it all possible. Sara looked at Olivia and saw the child she somehow always believed would come from her gift.
'I'm just so happy right now,' Emma told WGAL8, holding back tears.'To see her… it's just beautiful.'
For a long time, Emma wasn't sure this day would ever come. And for Sara, this moment affirmed everything she had hoped her donation would mean.
Related: A womb transplant between sisters led to this history-making birth—and new hope for families everywhere
Until recently, women born without a uterus had few options if they wanted to become parents. Adoption, surrogacy, and gestational carriers were paths forward—but carrying their own child wasn't one of them.
That's starting to change. Uterine transplant is a new and evolving medical procedure that offers hope to women with uterine factor infertility (UFI)—a condition that affects around 1 in every 500 women. The surgery involves transplanting a healthy uterus into a recipient who does not have one, followed by IVF and, if successful, a full-term pregnancy.
Penn Medicine is one of the few places in the country leading this breakthrough. As of now, eight babies—including Olivia—have been born through its program. And after years in clinical trial, the procedure is now available to qualifying patients outside of the research phase.
Still, it's not an easy road. The process involves complex surgeries, hormone therapy, IVF cycles, and careful monitoring. Costs are high, and not all insurance plans cover the procedure—though that's slowly beginning to change as awareness grows.
What was once unimaginable is now a real, if challenging, option. And with each successful birth, the medical world moves one step closer to making it more accessible.
Sara's gift went beyond the physical; she offered someone the chance at a new beginning. Her decision to donate her uterus came after her own years of motherhood were complete. But for Emma, that gift meant the chance to carry a child, feel the kicks, go through labor, and finally hold her baby in her arms.
It's not a kind of donation people talk about often. Blood, kidneys, bone marrow—those are more familiar. But uterus donation? It's a quieter, less understood act of generosity that sits at the intersection of medicine, motherhood, and meaning.
Sara's story opens a door—for Emma, and for other women who may now see uterus donation as a way to give back. It's a form of reproductive solidarity that speaks to something deeply maternal: the instinct to nurture, even if it's for someone else's child.
'I will tell [Olivia] that Sara made this possible for us,' Emma told WGAL8, 'That's one of the first things I'll tell her.'
Their story is rare, yes—but it doesn't have to be. With growing awareness, more donors may come forward. And more women who've been told 'you'll never carry' may finally get to hear 'yes, you can.'
Related: A woman born without a uterus just gave birth
Emma and Sara's journey is personal, but its impact reaches far beyond their lives. For every woman born without a uterus—or who lost hers to illness or surgery—this story signals something powerful: the path to motherhood is evolving.
Uterine transplant is still new. It's still complicated. But it exists. And for many, just knowing this option is real can spark hope where there once was none. It gives language to a kind of grief many women carry silently, and a possibility they may never have imagined.
It also challenges our idea of what motherhood looks like. One woman carried the baby. One woman made that possible. Both are mothers in every sense of the word. This story expands what family, identity, and connection can mean—through science, through compassion, and through a belief in what's possible when women support one another in the most literal way.
There's something deeply sisterly about it all. Two moms, connected by biology and bravery, each with their own role in a child's beginning.
Every pregnancy has a story behind it—but few are quite like this. A woman gave her uterus to a stranger. That stranger carried a baby who will grow up knowing she was born from two kinds of love.
These stories deserve to be heard—for their power, and for the possibilities they unlock. They introduce new options. They remind us that motherhood doesn't always follow a straight path.
If this story moved you, ask yourself:
Would you ever consider donating your uterus once your family is complete?
Should insurance companies be covering procedures like this?
What does it mean to expand the definition of motherhood in our lifetime?
There are no right or wrong answers. Just the hope that stories like Emma and Sara's will spark more conversations—and maybe even more miracles.
Olivia won't remember the day her two moms met. But one day, she'll hear the story—how one woman gave, another carried, and both believed in something bigger than themselves.
And maybe, when she grows up, this kind of birth won't feel rare. Maybe it will just feel like one of the many ways families are formed, with love and courage at the center.
For now, she is a living reminder of what's possible—when science catches up to hope, and when women show up for each other in extraordinary ways.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
RFK Jr. pulls funding for mRNA vaccines as scientists pursue breakthrough treatments for HIV, cancer, the flu and more
Health Secretary Robert F. Kennedy Jr. announced Tuesday that the federal government is canceling nearly $500 million in funding for the development of mRNA vaccines, a revolutionary new technology that was first put into widespread use during the COVID-19 pandemic. In a video explaining the decision posted to social media, Kennedy said that the Department of Health and Human Services has determined that 'mRNA technology poses more risk than benefits' for respiratory viruses like COVID-19. He also claimed that the pandemic showed 'mRNA vaccines don't perform well against viruses that affect the upper respiratory tract.' That statement runs counter to a wide body of research finding that COVID vaccines saved millions — if not tens of millions — of lives over the course of the pandemic. A total of 22 projects funded by a government agency called the Biomedical Advanced Research and Development Authority (BARDA) will be affected by the funding freeze, according to the department. A few projects that are in their final stages will be allowed to continue, but 'no new mRNA-based projects will be initiated.' 'This isn't just about vaccines. It's about whether we'll be ready when the next crisis hits. Cutting mRNA development now puts every American at greater risk,' Rick Bright, who directed BARDA in the early stages of the pandemic before being reassigned by the Trump administration, told NBC News. The decision doesn't mean that research into mRNA vaccines will stop entirely, but it does cut off a major source of funding that helped the vaccines become a reality in the first place. By the time the pandemic had started, the government had already given an estimated $337 million in grants for research into mRNA vaccines. That support over the course of decades put scientists in a position to make COVID vaccines available to the public at a record-shattering pace of less than a year. How do mRNA vaccines work? The 'm' in mRNA stands for messenger. In the most basic terms, it's a piece of genetic code that tells our cells what to do. Scientists have discovered how to harness this process to make vaccine development much faster and less expensive. Traditional vaccines typically use a dead or weakened version of a virus to stimulate an immune response that effectively teaches the body how to combat the real version if it ever encounters it. These types of vaccines can take a long time to develop because they rely on the slow, often complicated process of cultivating and modifying the actual virus into a safe and effective form. Using mRNA is much faster because the crucial ingredients can be created and customized in a lab. It took Moderna just two days to produce its mRNA vaccine for COVID in January 2020, before most people had ever even heard of the virus. The vaccines carry a snippet of mRNA that instructs the body to produce a small portion of a virus, usually a protein on its outer membrane, which is enough to trigger the same type of immune response that is prompted by traditional vaccines. The quicker process also means that existing mRNA vaccines can be modified more rapidly when viruses evolve. Despite Kennedy's claims, mRNA-based COVID vaccines have been found to be just as effective at preventing severe infections and death as vaccines made using other methods. After the vaccines became widely available, unvaccinated people were 11 times more likely to die of COVID than those who were fully vaccinated, according to data from the Centers for Disease Control and Prevention. Two researchers who helped achieve early breakthroughs in mRNA vaccines were awarded the Nobel Prize in 2023. Applications beyond COVID The introduction of COVID vaccines didn't just mark a turning point in the deadliest pandemic in modern history. It also provided evidence of mRNA's potential to protect people from a whole range of diseases. Just last week, researchers released promising results from early trials of new mRNA-based vaccines for HIV, a huge breakthrough in a pursuit that has confounded scientists for more than 40 years. There have been tremendous strides made in drugs that protect people from catching the virus or keep them healthy if they do contract it, but the limitations of those treatments still mean that more than 600,000 people are dying every year of AIDS — mostly in the developing world. Experts see a potential vaccine as a key to finally conquering the virus. There is also optimism that mRNA could be an effective tool in combating the seasonal flu. Current flu vaccines vary widely in effectiveness from year to year, and are only about 60% effective at their best, because it can be hard for experts to predict which strain of the virus will be more dominant in any given flu season. Several pharmaceutical companies are developing mRNA flu vaccines that could become a powerful tool for fighting influenza because of how quickly they can be adapted to match the nature of the virus at any given time. That speed could be especially important if a novel flu strain, like bird flu, causes a severe outbreak. There is even some promise that mRNA might one day be used to make a universal flu vaccine that covers all strains. The holy grail for mRNA is cancer. Though vaccines are typically used to prevent disease, there are several vaccines in development that show 'real hope' of being an effective treatment for people with cancer. Those include 'individualized' vaccines that are custom-made for each patient's specific needs. An mRNA vaccine for RSV is already available to certain high-risk adults. Other possible applications include the Zika virus and cytomegalovirus, an infection that is particularly dangerous for babies and people with compromised immune systems. Though experts say the rollback of U.S. government funding is a setback for these projects, some also expressed optimism that mRNA breakthroughs will continue to come even without America's support. 'Will this dent what's going on in the U.S.? Unquestionably,' Kate Bingham, who led the United Kingdom's COVID vaccine task force, told the Guardian. 'Does that mean it's negative for the world? Not necessarily.' Solve the daily Crossword
Fast Company
23 minutes ago
- Fast Company
Sources reveal the Trump administration's plans for cutting U.S. drug prices
The Trump administration has been talking to drugmakers about ways to raise prices of medicines in Europe and elsewhere in order to cut drug costs in the United States, according to a White House official and three pharmaceutical industry sources. U.S. officials told drug companies it would support their international negotiations with governments if they adopt 'most favored nation' pricing under which U.S. drug costs match the lower rates offered to other wealthy countries, the White House official said. The U.S. is currently negotiating bilateral trade deals and setting tariff rates on the sector. The Trump administration has asked some companies for ideas on raising prices abroad, two of the sources said, describing multiple meetings over several months aimed at lowering U.S. prices without triggering cuts to research and development spending drugmakers insist would result. The White House official called the effort collaborative, saying both sides were seeking advice from each other. The U.S. pays more for prescription drugs than any other country, often nearly three times as much as other developed nations. President Donald Trump has repeatedly said he wants to narrow this gap to stop Americans from being 'ripped off.' The previously unreported discussions reflect the challenges Trump faces to achieve that goal, and are the backdrop to the letters he sent last week to CEOs of 17 major drugmakers, urging them to cut U.S. prices to match those paid overseas. Unlike in the U.S., where market forces determine drug prices, European governments typically negotiate directly with companies to set prices for their national healthcare systems. Anna Kaltenboeck, a health economist at Verdant Research, said European nations have leverage to drive pricing and are sometimes willing to walk away from purchasing medicines they deem too expensive. Drugmakers generate most of their sales in the U.S. The Pharmaceutical Research and Manufacturers of America — the industry's main lobby group — has always argued that cutting U.S. prices would stifle innovation by lowering R&D spending. PhRMA declined to comment on the private meetings. Kaltenboeck said past studies had shown that drugmakers made enough money in the U.S. to more than fund their entire global R&D spends. 'Prices can come down in the United States without being increased in other countries, and we can still get innovation,' she said. TOP PRIORITY Despite the Trump administration's tariff threats and pressure to move more manufacturing to the U.S., the push to raise European drug prices is its top priority in discussions with industry, according to a senior executive at a European drugmaker, who spoke on condition of anonymity about the confidential meetings. 'This is the key conversation right now with PhRMA and every company getting that message from Pennsylvania Avenue to a point that we are already executing on it,' the executive said, referring to the White House address. The company had already met with European governments on the issue, the executive added. An E.U. Commission spokesperson said it is in regular contact with the pharma industry and pointed to an agreement with the U.S. that should it impose tariffs on pharmaceuticals, they would be capped at 15%. When asked how the administration would support international drug price negotiations, the White House official referred Reuters to Trump's most favored nation executive order from May. That order directed trade officials to pursue trade and legal action against countries keeping drug prices below fair market value. In last week's letters, Trump complained that since the May executive order, most industry proposals had simply shifted blame for high prices or requested policy changes that would result in billions in industry handouts. A second source, a pharmaceutical executive who was not authorized to speak on the matter, said the Trump administration has been continually meeting with representatives of his company and had discussed strategies for raising drug prices internationally. 'There's a big push from the administration to drive up prices outside the U.S.,' the executive said. The executive said the Trump administration had been looking at using trade talks with the UK and EU as leverage, and considered pressuring countries to spend a higher percentage of GDP on new medicines or offering tariff breaks in exchange for higher drug spending. It was understood that the UK deal specifically aims to get the country to ramp up investment in branded medicines over time, the executive said. A spokesperson for the UK government said it would continue to work closely with the U.S. and its own pharmaceutical industry to understand the possible impact of any changes to drug pricing, without commenting on the trade talks. In April, over 30 industry CEOs including those from AstraZeneca, Bayer and Novo Nordisk signed a letter to European Union President Ursula von der Leyen saying Europe needed to rethink its pricing policies. 'It's going to be very difficult for a country that already has the ability to control what it spends to go in the other direction,' Kaltenboeck said, 'and it doesn't make much sense for them politically.'
CBS News
24 minutes ago
- CBS News
Weiss Hospital could face closure when kicked off Medicare, Medicaid Friday, report says
Weiss Hospital in Chicago's Uptown neighborhood will be removed from the Medicare and Medicaid programs Friday, and a report suggests it could face closure. The Department of Health and Human Services is removing Weiss from the federal health care programs, saying the hospital failed to meet their standards of care. A nurse in the hospital's Emergency Department told the Chicago Sun-Times they expect to shut down Friday morning at 7 a.m. They said they were informed of that decision by their supervisor, and also noted no staff schedule has been set beyond Saturday. CBS News Chicago has leaned more about the exact reasons the hospital was deemed noncompliant with federal rules. Notably, a July 12 report by the Centers for Medicare and Medicaid Services did not cite the hospital's broken air conditioning as a reason. Rather, the report detailed multiple failures related to nursing care, along with a failure related to pharmaceutical record-keeping.
